| Quarterly Financials | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 399 | 426 | 425 | 437 | 484 | 555 | 441 | 557 | 539 | 628 | 437 | 533 | 602 | 712 | 607 | 623 | 654 | 773 | 660 | 784 | 803 | 1,017 | 832 | 932 | 883 | 933 | 840 | 908 | 962 | 1,037 |
| Expenses | 262 | 280 | 297 | 292 | 327 | 374 | 300 | 325 | 366 | 403 | 297 | 364 | 408 | 443 | 430 | 464 | 438 | 508 | 472 | 552 | 555 | 680 | 596 | 663 | 626 | 600 | 620 | 646 | 660 | 674 |
| EBITDA | 138 | 146 | 128 | 145 | 158 | 181 | 142 | 231 | 174 | 225 | 140 | 170 | 193 | 269 | 177 | 160 | 216 | 265 | 188 | 232 | 248 | 337 | 236 | 268 | 257 | 333 | 220 | 261 | 302 | 363 |
| Operating Profit % | 33 % | 32 % | 27 % | 30 % | 30 % | 30 % | 29 % | 30 % | 30 % | 34 % | 30 % | 30 % | 30 % | 33 % | 28 % | 24 % | 32 % | 33 % | 27 % | 28 % | 29 % | 32 % | 26 % | 27 % | 27 % | 35 % | 22 % | 27 % | 30 % | 34 % |
| Depreciation | 35 | 34 | 37 | 40 | 43 | 44 | 47 | 53 | 57 | 62 | 66 | 69 | 70 | 70 | 75 | 76 | 79 | 80 | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 |
| Interest | 5 | 7 | 8 | 8 | 8 | 8 | 7 | 8 | 10 | 9 | 7 | 7 | 7 | 7 | 8 | 1 | 9 | 6 | 9 | 12 | 14 | 10 | 11 | 13 | 11 | 13 | 12 | 13 | 12 | 16 |
| Profit Before Tax | 98 | 104 | 83 | 97 | 107 | 129 | 87 | 170 | 107 | 153 | 66 | 94 | 117 | 192 | 95 | 82 | 128 | 179 | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 241 |
| Tax | 16 | 20 | 17 | 19 | 20 | 29 | 15 | 42 | 15 | 33 | 8 | 10 | 14 | 32 | 17 | 16 | 24 | 31 | 19 | 28 | 30 | 52 | 30 | 34 | 27 | 20 | 26 | 31 | 50 | 57 |
| Net Profit | 82 | 85 | 66 | 78 | 87 | 100 | 72 | 128 | 92 | 120 | 58 | 84 | 102 | 161 | 77 | 67 | 104 | 148 | 74 | 102 | 110 | 179 | 93 | 117 | 112 | 189 | 76 | 106 | 131 | 183 |
| EPS in ₹ | 4.14 | 4.27 | 3.34 | 3.96 | 2.20 | 2.53 | 1.82 | 3.23 | 2.32 | 3.03 | 1.47 | 2.12 | 2.57 | 4.04 | 1.91 | 1.64 | 2.57 | 3.71 | 1.85 | 2.55 | 2.74 | 4.36 | 2.33 | 2.90 | 2.78 | 4.70 | 1.89 | 2.64 | 3.27 | 4.56 |
Syngene International
605.35
-5.35
(-0.88%)
Market Cap
24,367.58 Cr
EPS
12.71
PE Ratio
52.12
Dividend Yield
0.20 %
Industry
Healthcare52 Week High
960.60
52 Week Low
606.20
PB Ratio
5.21
Debt to Equity
0.17
Sector
Healthcare Technology
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
605.35 | #1 24,367.58 | #3 52.12 | #1 3,579.20 | #4 9.66 | #1 510 | #7 -2.81 | 31.87 | |
541.35 | 12,989.94 | #1 32.21 | 2,665.90 | 12.77 | 337 | 24.05 | 46.03 | |
134.81 | 2,939.85 | - | 32.80 | #1 49.09 | -105 | 6.46 | 59.00 | |
945.00 | 2,100.05 | 35.58 | 322.30 | 0.22 | 41 | 112.87 | 46.98 | |
70.00 | 164.84 | - | 769.70 | -22.39 | -59 | 17.26 | 39.24 | |
7.30 | 107.99 | - | 67.20 | -65.97 | -120 | #1 2,371.43 | 33.22 | |
39.00 | 61.76 | 89.84 | 40.30 | 8.04 | -1 | 120.00 | 38.89 | |
15.00 | 26.30 | 33.09 | 80.00 | -3.26 | 2 | -80.00 | 35.36 | |
19.08 | 12.07 | - | 9.80 | 40.00 | -9 | -380.00 | 36.04 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
9.66 %
Net Income Growth
9.82 %
Cash Flow Change
26.55 %
ROE
-6.70 %
ROCE
-3.05 %
EBITDA Margin (Avg.)
0.23 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 |
| Current Assets | 1,720 | 1,764 | 1,613 | 1,807 | 2,206 | 2,425 | 1,959 |
| Capital Work in Progress | 155 | 274 | 234 | 237 | 346 | 177 | 838 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 919 | 548 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,791 | 2,069 | 1,916 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 |
| Current Liabilities | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,188 | 1,144 |
| Non Current Liabilities | 685 | 607 | 448 | 929 | 1,037 | 1,025 | 750 |
| Total Equity | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 4,258 |
| Reserve & Surplus | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 |
| Share Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 18 | -88 | 28 | 130 | -62 | -172 | -4 |
| Investing Activities | -349 | -646 | -424 | -629 | -611 | -653 | -494 |
| Operating Activities | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 |
| Financing Activities | -79 | -72 | -226 | 58 | -31 | -343 | -552 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 70.58 % | 70.43 % | 70.42 % | 70.41 % | 70.41 % | 70.29 % | 64.86 % | 64.86 % | 54.88 % | 54.80 % | 54.79 % | 54.79 % | 54.79 % | 54.72 % | 54.72 % | 52.74 % | 52.74 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 20.92 % | 20.63 % | 20.72 % | 20.64 % | 19.47 % |
| DIIs | 4.02 % | 3.81 % | 4.03 % | 3.64 % | 3.26 % | 2.79 % | 4.96 % | 7.04 % | 10.73 % | 11.20 % | 9.94 % | 13.08 % | 15.80 % | 16.80 % | 17.48 % | 19.53 % | 21.50 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.05 % | 8.29 % | 8.46 % | 9.20 % | 9.22 % | 9.02 % | 8.81 % | 8.57 % | 8.39 % | 8.10 % | 7.53 % | 7.24 % | 6.45 % | 6.08 % | 5.45 % | 5.59 % | 5.08 % |
| Others | 17.35 % | 17.46 % | 17.09 % | 16.76 % | 17.11 % | 17.90 % | 21.36 % | 19.52 % | 25.98 % | 25.90 % | 27.73 % | 24.89 % | 2.03 % | 1.77 % | 1.62 % | 1.50 % | 1.21 % |
| No of Share Holders | 1,15,632 | 1,26,395 | 1,36,749 | 1,37,892 | 1,33,610 | 1,28,278 | 1,34,334 | 1,27,964 | 1,24,014 | 1,25,455 | 1,25,992 | 1,21,880 | 1,15,850 | 1,20,018 | 1,07,338 | 1,28,806 | 1,25,090 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 0.5 | 0.00 | 0.00 | 1 | 1.25 | 1.25 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.33 | 0.34 | 0.21 | 0.00 | 0.00 | 0.17 | 0.18 | 0.17 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Jul 2025 |  Annual General Meeting | NA | 23 Jul 2025 | 735.45 | 610.70 |
| 23 Apr 2025 |  Quarterly Result Announcement | NA | 23 Apr 2025 | 697.45 | 735.45 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 859.80 | 828.15 |
| 23 Oct 2024 | Quarterly Result Announcement | NA | 23 Oct 2024 | 884.35 | 838.90 |
| 24 Jul 2024 | Annual General Meeting | NA | 24 Jul 2024 | 701.05 | 757.75 |
| 28 Jun 2024 |  Dividend | ₹ 1.25 /share | 28 Jun 2024 | 701.05 | 713.15 |
| 30 Jun 2023 | Dividend | ₹ 0.75 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 30 Jun 2023 | Dividend | ₹ 0.50 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 12 Jun 2019 |  Bonus | 1:1 | 11 Jun 2019 | 340.05 | 336.35 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 days ago
6 days agoGrant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 24, 2025
Apr 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 23, 2025
Apr 23, 2025Appointment Of Secretarial Auditors.Apr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-AllotmentApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Apr 23, 2025Audited Financial Results For Quarter & Year Ended March 31 2025.Apr 23, 2025
Apr 23, 2025Board Meeting Outcome for Outcome Of The Board Meeting - April 23 2025Apr 23, 2025
Apr 23, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 22, 2025
Apr 22, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 22, 2025
Apr 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 12, 2025
Apr 12, 2025Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Year Ending March 31 2025; And To Consider The Recommendation Of Final Dividend If Any.Apr 08, 2025
Apr 08, 2025Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Apr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Intimation Of An Update On The Tax Litigations.Mar 29, 2025
Mar 29, 2025Reminder - Communication To Shareholders For Claiming Unclaimed Dividends.Mar 28, 2025
Mar 28, 2025Intimation Of Disclosure On Receipt Of Order From The Income Tax Department.Mar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Intimation Of Additional Disclosure On Update On The Tax LitigationsMar 27, 2025
Mar 27, 2025Intimation Of Additional Disclosure On Receipt Of Orders From The Income Tax DepartmentMar 27, 2025
Mar 27, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 24, 2025
Mar 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 24, 2025
Mar 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Mar 23, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Mar 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Mar 10, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Mar 07, 2025Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Mar 01, 2025
Mar 01, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 27, 2025
Feb 27, 2025Update On Pre-Approval And Cgmp Inspection By United States Food & Drug Administration (USFDA).Feb 21, 2025
Feb 21, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 15, 2025
Feb 15, 2025Intimation Of Cancellation Of Meetings With Analysts/Institutional InvestorsFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Feb 05, 2025Technical Indicators
RSI(14)
Neutral 31.87
ATR(14)
Less Volatile 22.53
STOCH(9,6)
Oversold 10.74
STOCH RSI(14)
Oversold 8.31
MACD(12,26)
Bearish -7.20
ADX(14)
Strong Trend 27.28
UO(9)
Bearish 43.10
ROC(12)
Downtrend And Accelerating -15.72
WillR(14)
Oversold -96.97
About Syngene International
Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.
Listing Date
11 Aug, 2015(9 Years,
28 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
